Astigmatism

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on: 
화요일, 5월 7, 2024
General Health, Surgery, Medical Devices, Health, Optical, Sale, Near-sightedness, Table, IOL, Presbyopia, Investment, EVO, Research, Depreciation, STAAR, ICL, Patient, Access, Marketing, Adjustment, Fruit, Cataract, Advertising, Astigmatism, GAAP, Growth

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points: 
  • STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
  • Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
  • Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
  • Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
화요일, 5월 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

GOOD Vision Unveils K-Shape™: A Revolutionary Corneal Topographer at The International Exhibition of Inventions of Geneva

Retrieved on: 
금요일, 5월 3, 2024
COVID, Corneal opacity, Astigmatism, News, KONG, Finance, Research, Workflow, Optometry, Invention, Patient, Approximation error, Corneal topography, Data analysis, Health, Diagnosis, Algorithm, Growth, Technical, World's fair

The innovative topographer outperforms existing devices with its flexibility, compact size, utilisation of normative data from Chinese populations, and affordability.

Key Points: 
  • The innovative topographer outperforms existing devices with its flexibility, compact size, utilisation of normative data from Chinese populations, and affordability.
  • Dr. Jason Lau, the Technical Director at GOOD Vision, said, "At GOOD Vision, we're setting new standards in eye care with K-ShapeTM.
  • The debut of GOOD Vision's corneal topographer marks a transformative moment in the industry, significantly enhancing practitioners' ability to deliver personalised care.
  • GOOD Vision invites attendees to visit their booth at The International Exhibition of Inventions of Geneva to experience first-hand the future of corneal topography.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
수요일, 5월 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on: 
월요일, 4월 29, 2024
Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
  • STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
  • To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
  • The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

Retrieved on: 
목요일, 4월 4, 2024
Optical, Health, Surgery, Medical Devices, ICL, U.S. FDA, Growth, Presbyopia, Near-sightedness, Sale, EVO, Bank statement, Investment, FDA, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
  • “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results including a record quarter in the U.S.,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus.
  • The Company expects to report complete first quarter financial results and discuss its fiscal 2024 outlook during its quarterly earnings call on or about May 8, 2024.

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

Retrieved on: 
화요일, 4월 2, 2024
Biotechnology, Practice Management, Optical, Surgery, General Health, Health, Hospitals, Other Health, Presbyopia, ASCRS, Patient, Social media, Near-sightedness, Lens, Cataract, Astigmatism, EVO, STAAR, Surgeon, Publication, Society, Booth, FACS, Multimedia, Behavior, FDA, Reflexive relation, Communications satellite

Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.

Key Points: 
  • Furthering the momentum behind its flagship product, EVO ICL, the company is proud to showcase the clinical, practice and innovation advantages through a series of posters, presentations and educational programs.
  • STAAR Surgical can be found at Booth 527 and additional ASCRS event information is available at https://ascrs.org/annual-meeting .
  • View the full release here: https://www.businesswire.com/news/home/20240402599401/en/
    “EVO ICL is the next logical step in refractive innovation.
  • The website offers surgeons access to a wealth of resources, including publications, key clinical outcomes data, and more.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
수요일, 3월 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

Retrieved on: 
월요일, 3월 18, 2024
Optical, Health, Surgery, Medical Devices, ICL, Presbyopia, Patient, Iris, American Academy, EVO, Eye, Surgeon, Multimedia, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240318771746/en/
    “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens milestone,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • “EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction.
  • Myopia (nearsightedness) is the most common refractive visual error and is a global epidemic that is expected to impact over half the world’s population by 2050.2
    1 EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Retrieved on: 
화요일, 3월 12, 2024
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Other Health, Eli Lilly, ICL, Boston Scientific, Growth, AstraZeneca, Presbyopia, Eli Lilly and Company, University, Near-sightedness, Art, Columbia University, Indiana State University, EVO, STAAR, Senior, MBA, Bayer, Campbell University, Nursing credentials and certifications, Marketing, CFA, Waters Corporation, Guidant, Retirement, Arthur Butcher, Economics, Astigmatism, Management

“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.

Key Points: 
  • “Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • "Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction.
  • He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
  • We wish her the best in her future endeavors.”
    With the appointment of Messrs. Butcher and Jiang to the Board, the STAAR Surgical Board is now comprised of eight directors, seven of whom are independent non-employee directors.